Seroprevalence of COVID-19 among healthcare workers in Hong Kong during the first 2 years of the COVID-19 pandemic (2020-2021): a longitudinal cohort study.

Publication date: May 15, 2026

In the first 2 years of the COVID-19 pandemic, Hong Kong adopted strict public health and social measures to stop community transmission of SARS-CoV-2. These include border screening and control, isolation of cases and quarantine of their contacts and universal masking. During this period, attack rates in Hong Kong were among the lowest globally. To estimate the seroprevalence of COVID-19 among healthcare workers (HCWs) in Hong Kong in 2020 and 2021. We reviewed contact tracing data from the Hong Kong Department of Health to identify COVID-19 cases reported among HCWs. Between June 2020 and December 2021, we conducted a longitudinal cohort study to estimate the seroprevalence of COVID-19 among HCWs working in hospitals and clinics in Hong Kong during the first 2 years of the COVID-19 pandemic. Overall seropositivity of COVID-19 by plaque reduction neutralisation test during the first (May-October 2020) and second round (November 2020-April 2021) of the study was 0% (95% CI 0. 00% to 0. 49%) and 0. 52% (95% CI 0. 14% to 1. 33%). After COVID-19 vaccines were offered to HCWs in February 2021, seroprevalence by surrogate virus neutralisation assay among cohort participants who provided biannual blood samples rose to 68. 7% (95% CI 65. 9%, 71. 3%) and 80. 2% (95% CI 76. 8%, 83. 2%) in round 3 (May-October 2021) and the first 2 months of round 4 (November-December 2021). Seroprevalence in Hong Kong HCWs in our study was low despite considerable exposure to confirmed COVID-19 cases in some study participants. However, the low rate of community transmission may have also contributed to the observed low seroprevalence among HCWs in our cohort.

Open Access PDF

Concepts Keywords
2months Adult
December Contact Tracing
Healthcare COVID-19
Pandemic COVID-19
EPIDEMIOLOGY
Female
Health
Health Personnel
Hong Kong
Humans
Longitudinal Studies
Male
Middle Aged
SARS-CoV-2
Seroepidemiologic Studies

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Severe Acute Respiratory Syndrome
disease MESH emerging infectious diseases
disease MESH infection
disease MESH dis
drug DRUGBANK Indoleacetic acid
disease MESH influenza
disease MESH plan
disease MESH included
disease MESH asymptomatic infections
drug DRUGBANK Etoperidone
disease MESH face
disease MESH fever
disease MESH respiratory infections
disease MESH cough
disease MESH sore throat
disease MESH runny nose
disease MESH emergency
drug DRUGBANK Trestolone
disease MESH Lam
pathway REACTOME Translation
disease MESH SWS
disease MESH fatigue
disease MESH SMS
disease MESH EJM
disease MESH MCS
disease MESH Coronavirus Infection
disease MESH Reinfection

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *